Endometrial Cancer - Global Drug Forecast and Market Analysis to 2030

1.1 Large Market Growth Forecast for the Endometrial Cancer Market During 2020-2030
1.2 Immunotherapy Set to Become the Standard of Care and Redefine Patient Segmentation
1.3 Launches of Novel Therapies Will Significantly Address the Current Lack of Approved Therapies and Patient Segmentation
1.4 Immunotherapy and Novel Drug Classes to Lead the Endometrial Cancer Market
1.5 What Do Physicians Think?

2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports

3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Classification or Staging Systems

4.1 Disease Background
4.2 Global and Historical Trends
4.3 Risk Factors and Comorbidities
4.4 Forecast Methodology
4.4.1 Sources
4.4.2 Forecast Assumptions and Methods
4.4.3 Diagnosed Incident Cases of Endometrial Cancer
4.4.4 Diagnosed Incident Cases of Endometrial Cancer by FIGO Stage at Diagnosis
4.4.5 Diagnosed Incident Cases of Endometrial Cancer by Subtype
4.4.6 Diagnosed Incident Cases of Endometrial Cancer by Associated Biomarker
4.4.7 Five-Year Diagnosed Prevalent Cases of Endometrial Cancer
4.5 Epidemiological Forecast for Endometrial Cancer (2020-2030)
4.5.1 Diagnosed Incident Cases of Endometrial Cancer
4.5.2 Age-Specific Diagnosed Incident Cases of Endometrial Cancer
4.5.3 Diagnosed Incident Cases of Endometrial Cancer by FIGO Stage
4.5.4 Diagnosed Incident Cases of Endometrial Cancer by Subtype
4.5.5 Diagnosed Incident Cases of Endometrial Cancer with Associated Biomarkers
4.5.6 Diagnosed Incident Cases of Endometrial Cancer with HER2 Positivity by FIGO Stage
4.5.7 Five-Year Diagnosed Prevalent Cases of Endometrial Cancer
4.6 Discussion
4.6.1 Epidemiological Forecast Insight
4.6.2 COVID-19 Impact
4.6.3 Limitations of Analysis
4.6.4 Strengths of Analysis

5.1 Diagnosis and Treatment Overview
5.2 KOL Insights on Disease Management

6.1 Overview

7.1 Overview
7.2 Lack of Approved Therapies and Established Treatment Guidelines for Recurrent Patients
7.3 Establish Tumor Sequencing as Standard of Care
7.4 Define Patients Groups that Would Benefit from Maintenance Therapy
7.5 Treatment Alternatives for Patients who Cannot Tolerate Chemotherapy or Have Become Chemo-Resistant

8.1 Overview
8.1.1 Identify Optimal Immunotherapy Combination Strategies and Define Preferred Treatment per Line of Therapy
8.1.2 Introduction of Novel Mechanisms of Action and Targets
8.2 Clinical Trial Design
8.2.1 Precedent for EC Clinical Trial Design and Importance for Ongoing Clinical Trials
8.2.2 Limitations of Current Clinical Trials

9.1 Overview
9.2 Promising Drugs in Clinical Development
9.2.1 PD-1/PD-L1 Inhibitors Plus Chemotherapy Under Investigation with a Maintenance Component
9.2.2 PD-1/PD-L1 Inhibitor Combinations with Either Chemotherapy or Targeted Therapies, Without a Maintenance Component
9.2.3 Novel Drug Classes Targeting the Unresectable and Relapsed Population
9.2.4 Promising Novel Therapies in Early-Stage Development

10.1 Overview
10.2 Competitive Assessment

11.1 Overview
11.2 Deal-Making Trends

Table 1: Endometrial Cancer: Key Metrics in the 8MM
Table 2: Stage Definitions for Endometrial Cancer
Table 3: Risk Factors for Endometrial Cancer
Table 4: 8MM, Diagnosed Incident Cases of Endometrial Cancer by Subtype, Women, Ages 18 Years, N, 2020
Table 5: Treatment Guidelines for Endometrial Cancer
Table 6: Endometrial Cancer Market - Global Drivers and Barriers, 2020-2030
Table 7: Key Events Impacting Sales for EC in the US, 2020-2030
Table 8: EC Market - Drivers and Barriers in the US, 2020-2030
Table 9: Key Events Impacting Sales for EC in the 5EU, 2020-2030
Table 10: EC Market - Drivers and Barriers in the 5EU, 2020-2030
Table 11: Key Events Impacting Sales for EC in Japan, 2020-2030
Table 12: Endometrial Cancer Market - Drivers and Barriers in Japan, 2020-2030
Table 13: Key Events Impacting Sales for EC in Canada, 2020-2030
Table 14: EC Market - Drivers and Barriers in Canada, 2020-2030
Table 15: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figure 1: Global Sales Forecast by Country for Endometrial Cancer in 2020 and 2030
Figure 2: Analysis of the Company Portfolio Gap in Endometrial Cancer During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that the Publisher Expects to be Licensed for the Treatment of Endometrial Cancer During the Forecast Period
Figure 4: Impact of the Estrogen-Progesterone Cycle in Determining Endometrial Thickness
Figure 5: Prognostic Groups in Endometrial Cancer According to TCGA
Figure 6. 8MM, Diagnosed Incidence of Endometrial Cancer (Cases per 100,000 population), Women, Ages =18 Years, 2020 and 2030
Figure 7: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Endometrial Cancer
Figure 8: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Endometrial Cancer by FIGO Stage
Figure 9: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Endometrial Cancer by Subtype
Figure 10: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Endometrial Cancer with Associated Biomarker
Figure 11: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Endometrial Cancer with HER2 Positivity by FIGO Stage
Figure 12: 8MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of Endometrial Cancer
Figure 13: Diagnosed Incident Cases of Endometrial Cancer, 8MM, Women, Ages =18 years, 2020
Figure 14: 8MM, Diagnosed Incident Cases of Endometrial Cancer by Age, Women, N, 2020
Figure 15: 8MM, Diagnosed Incident Cases of Endometrial Cancer by FIGO Stage, Women, Ages =18 Years, N, 2020
Figure 16: 8MM, Diagnosed Incident Cases of Endometrial Cancer with Associated Biomarker, Women, Ages =18 Years, N, 2020
Figure 17: 8MM, Diagnosed Incident Cases of Endometrial Cancer with HER2 Positivity by FIGO Stage, Women, Ages =18 Years, N, 2020
Figure 18: 8MM, Five-Year Diagnosed Prevalent Cases of Endometrial Cancer, Women, Ages =18 Years, N, 2020
Figure 19: Treatment Overview for Endometrial Cancer
Figure 20: Unmet Needs and Opportunities in Endometrial Cancer
Figure 21: Projected Treatment Decisions to Determine Use of Various Pipeline Agents in the First-Line Setting
Figure 22: Overview of the Development Pipeline in Endometrial Cancer
Figure 23: Key Late-Stage Trials for the Promising Pipeline Agents that the Publisher Expects be Licensed for Endometrial Cancer in the 8MM During the Forecast Period
Figure 24: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, chemotherapy
Figure 25: Analysis of the Company Portfolio Gap in Endometrial Cancer During the Forecast Period
Figure 26: Global (7MM) Sales Forecast by Country for Endometrial Cancer in 2020 and 20230
Figure 27: Sales Forecast by Class for EC in the US in 2020 and 2030
Figure 28: Sales Forecast by Class for EC in the 5EU in 2020 and 2030
Figure 29: Sales Forecast by Class for EC in Japan in 2020 and 2030
Figure 30: Sales Forecast by Class for EC in Canada in 2020 and 2030